Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ovosicare ProFIV
- Development stage
- Unknown
- Lead developer
- Procare Health
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Small Molecules, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Ovosicare ProFIV is a multi-ingredient nutraceutical developed by Procare Health, specifically formulated to support fertility in women undergoing assisted reproductive technology (ART) treatments, such as in vitro fertilization (IVF), artificial insemination, or oocyte preservation. The product features Caronositol Fertility, a patented combination of myo-inositol and D-chiro-inositol in a 3.6:1 ratio, which is designed to improve oocyte quality. It is notably distinguished by a high concentration of live Lactobacillus probiotics (L. crispatus, L. rhamnosus, and L. acidophilus) intended to optimize the vaginal and endometrial microbiome, thereby reducing the risk of embryo implantation failure. Additional active components include Pomanox pomegranate extract for antioxidant protection, Quatrefolic (a bioavailable folate) to normalize homocysteine levels, melatonin, coenzyme Q10, and S-adenosyl-L-methionine (SAMe) to support emotional well-being and reduce stress during fertility treatments. Ovosicare ProFIV is commercially available in sachet form for oral administration.
- Brand names
- Ovosicare ProFIV
- Other names
- Ovosicare Pro FIV
02
Targets
NADH:ubiquinone oxidoreductase subunit familyMTNR1B (Melatonin Receptor 2)MTNR1A (MT1)Folate receptor and transporter system
Beyond the preview
Go deeper on Ovosicare ProFIV.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ovosicare ProFIV.